^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Jingzhuda (entinostat) (HDAC inhibitor, HDAC1 inhibitor, HDAC2 inhibitor, HDAC3 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A single-arm, prospective, phase II clinical study of the combination of entinostat and oral paclitaxel in the treatment of HR+HER2- advanced breast cancer
Excerpt:
......
Trial ID:
Source:
Title:
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
Excerpt:
...- Patients with triple negative disease must have progressed through at least 1 prior chemotherapy regimen (administered in the adjuvant or metastatic setting); hormone receptor-positive patients must have progressed through two lines of hormonal therapy (administered in the adjuvant or metastatic setting), unless otherwise eligible as per below, and at least 1 prior chemotherapy regimen (administered in the adjuvant or metastatic setting) with...
Trial ID:
More C2 evidence
Source:
Title:
A Phase II, Two-Stage Study Evaluating the Efficacy of Entinostat in Combined with Fulvestrant in Locally Advanced or Metastatic Breast Cancer with Recurrence or Progression after CDK4/6 Inhibitor plus Endocrine Therapy
Excerpt:
......
Trial ID:
Less C2 evidence
Source:
Title:
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
Published date:
11/24/2021
Excerpt:
This phase 1 study (3 + 3 dose-escalation design) enrolled postmenopausal women with advanced/metastatic HR+ BC...Six patients (50%) achieved stable disease (SD) for ≥ 6 months, including one treated for > 19 months. Median progression-free survival was 13.9 months (95% CI 1.9-not calculable); median overall survival was not reached....Entinostat monotherapy and combined entinostat/exemestane were well tolerated in Japanese patients...
Secondary therapy:
exemestane
DOI:
10.1186/s12885-021-08973-4
Trial ID:
Source:
Title:
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer
Published date:
11/24/2021
Excerpt:
This phase 1 study (3 + 3 dose-escalation design) enrolled postmenopausal women with advanced/metastatic HR+ BC...Six patients (50%) achieved stable disease (SD) for ≥ 6 months, including one treated for > 19 months. Median progression-free survival was 13.9 months (95% CI 1.9-not calculable); median overall survival was not reached....Entinostat monotherapy and combined entinostat/exemestane were well tolerated in Japanese patients...
DOI:
10.1186/s12885-021-08973-4
Trial ID: